Currently, EYE is essentially a one product enterprise but that product has the potential of becoming the gold standard in the treatment of glaucoma going forward. The top end of the market (where the smart money resides) largely focuses on risk that is ultimately a function of operational diversification. This may be one of the reasons for the tardy EYE share price activity of late but that can change in a heartbeat particularly if there are performance metrics that provide confirmation of market status that is or will in the near future provide the returns forecast from such a product. My feeling is that EYE is currently in a transition phase where nothing has been actually confirmed in respect to its performance sustainability yet certainly implied in the distribution and sales data so far. Sometimes it takes time and patience to reach the critical mass point but usually when it does, the investment capital finds it and that is when the re rating of EYE will occur IMHO.
- Forums
- ASX - By Stock
- EYE
- CMS Proposes Major Increase in Reimbursement for Canaloplasty
CMS Proposes Major Increase in Reimbursement for Canaloplasty, page-339
-
- There are more pages in this discussion • 169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.5¢ |
Change
0.005(2.63%) |
Mkt cap ! $44.66M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 19.5¢ | $9.907K | 50.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 65104 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 51773 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 65104 | 0.195 |
3 | 202141 | 0.190 |
1 | 20980 | 0.185 |
2 | 71691 | 0.180 |
4 | 92714 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 51773 | 2 |
0.205 | 44282 | 2 |
0.210 | 223212 | 2 |
0.215 | 304291 | 5 |
0.230 | 103718 | 2 |
Last trade - 13.43pm 13/09/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online